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Abstract: The purpose of this article is to provide a description of a clinical pharmacy services 
program implemented in a renal transplant clinic to improve medication access and adherence 
as well as health and economic outcomes among renal transplant recipients (RTRs). Following 
a team-based planning process and an informal survey of RTRs, a clinical pharmacy service 
intervention was implemented in the Medical College of Georgia renal transplant clinic. As 
part of the intervention, a clinical pharmacist reviewed and optimized medication therapy, 
provided instructions on how to take medication, and assisted with enrollment into medication 
assistance programs. Signiﬁ  cant differences were found between RTRs who did and did not 
receive clinical pharmacy services on measures of adherence, health, economics, and quality 
of life. Clinical pharmacy services, as described in this article, have a positive impact on renal 
transplant recipients’ medication adherence, health and economic outcomes, and health-related 
quality of life. The ﬁ  ndings described here suggest that clinical pharmacy services are a viable 
and effective option for improving care for RTRs in an outpatient clinic setting.
Keywords: renal transplant recipients, immunosuppressant therapy adherence, health outcomes, 
economic outcomes
More than 179,000 kidney transplants have been performed in the United States since 
1995 (UNOS 2008). In that same time period, more than 316,000 individuals were 
added to the kidney transplant waiting list, and greater than 42,000 individuals died 
while awaiting a kidney (renal) transplant. For those who receive renal transplants, 
maintenance of graft (transplanted kidney) function and improved health are among the 
most important post-transplant goals. Immunosuppressant therapy (IST) is integral to 
graft maintenance and survival, yet 20% to 70% of renal transplant recipients (RTRs) 
are nonadherent to their IST (improperly take their IST; Frazier et al 1994; Greenstein 
and Siegal 1998; Chisholm et al 2001; Butler et al 2004; Dew et al 2007). After waiting 
more than 3 years, incurring health care expenditures of over US$300,000, and receiv-
ing a donated kidney for transplantation, it is a tragedy to lose graft function as the 
result of a preventable cause such as IST nonadherence. It is believed that more than 
one-third of graft failures are due to IST nonadherence (Gaston et al 1999). Butler and 
colleagues (2004) indicated that the odds of graft failure increased 7-fold in nonadherent 
RTRs compared to adherent RTRs, and concluded that signiﬁ  cant improvement in 
graft survival could be expected from effective interventions to improve adherence. 
One such potential intervention is the implementation of clinical pharmacy services 
among RTRs as part of their post-transplant care.
Several studies have been conducted that demonstrate the value of pharmacy 
services in improving medication therapy adherence and health-related outcomes in 
various patient populations (Nola et al 2000; Till et al 2003; Kiel and McCord 2005; 
Paulós et al 2005; Lee et al 2006; McCord 2006; Armour et al 2007; Clark et al 
2007; Murray et al 2007). For example, a pharmacy care program for elderly patients Patient Preference and Adherence 2008:2 288
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at risk for cardiovascular disease signiﬁ  cantly improved 
medication adherence and blood pressure levels (Lee et al 
2006). McCord (2006) found that drug therapy management 
and education services provided by a clinical pharmacist 
signiﬁ  cantly improved clinical indicators such as hemoglobin 
A1c levels among patients with diabetes. However, a review 
of the literature using PubMed, dates unlimited, produced 
very few studies of clinical pharmacy services as an inter-
vention to improve medication adherence and/or outcomes 
among RTRs, indicating that there is a paucity of research 
concerning pharmacy services to improve IST adherence 
and RTRs’ outcomes.
The value of pharmacist-provided care to transplant 
recipients has been recognized by the nation’s foremost 
transplant organization, the United Network for Organ Shar-
ing (UNOS). In order to qualify for UNOS membership, a 
transplant program should utilize at least one clinical phar-
macist as part of the transplant team to provide pharmaceuti-
cal care to solid organ transplant recipients (UNOS 2007). 
It is our contention that clinical pharmacy services would 
be beneﬁ  cial, not only as part of the care provided by the 
transplant team, but also in the outpatient transplant clinic 
setting. Thus, the purpose of this manuscript is to describe a 
successful program that utilizes clinical pharmacy services 
to improve medication adherence and outcomes of RTRs in 
an outpatient transplant clinic.
The Medical College of Georgia (MCG) Hospital and 
Clinics is a tertiary-care teaching hospital located in Augusta, 
Georgia. In late 1996, our team began exploring patient 
populations treated at MCG who could most beneﬁ  t from 
clinical pharmacy services. We focused on those patients with 
chronic conditions who were required to take complicated, 
long-term medication regimens. The renal transplant popula-
tion was immediately distinguished as a potential target for 
clinical pharmacy services for several reasons. MCG’s renal 
transplant clinic provides care for more than 500 RTRs who 
must adhere to complex, expensive medication regimens, 
and as stated previously, the health-related consequences 
to RTRs of nonadherence to medication regimens can be 
dire (Chisholm 2006). As a result, RTRs are at increased 
risk for medication nonadherence, drug – drug interactions, 
and related adverse events. Additionally, immunosuppres-
sant agents have inﬂ  uence on the cytochrome P450 system 
which also increases the possibility of drug interactions. 
According to anecdotal evidence, many patients served by 
the MCG renal transplant clinic were prone to medication 
nonadherence and/or suffered adverse drug events, and 
consequences of both included increased health care costs, 
negative health outcomes, and decreased quality of life. Our 
team hypothesized that clinical pharmacy services would 
increase medication adherence, reduce the number of adverse 
drug events, improve health outcomes, decrease health care 
costs, and increase quality of life among RTRs. We also 
believed that MCG’s renal transplant clinic health care 
team, consisting of two nephrologists, nurses, and physician 
assistants, could beneﬁ  t from the additional support provided 
by clinical pharmacy services. Therefore, we targeted RTRs 
and the MCG renal transplant clinic for clinical pharmacy 
services.
The ﬁ  rst step in developing a clinical pharmacy program 
speciﬁ  cally for the MCG renal transplant clinic was a series 
of brainstorming sessions in which causes of adverse health 
outcomes related to medication (particularly barriers to IST 
adherence) were discussed. Aspects of the Health Decision 
Model (Eraker et al 1984), particularly factors affecting 
health decisions (in this case, the decision to adhere to IST) 
such as knowledge and sociodemographic factors, were 
considered during these sessions. A Fishbone diagram 
(Figure 1) was developed as a visual representation of what 
our team believed to be the major causes of nonadherence to 
medication regimens among RTRs. To assess the accuracy of 
those causes or barriers identiﬁ  ed, we conducted an informal 
survey of RTRs at the renal transplant clinic. According to 
those surveyed, cost of IST and forgetfulness as well as other 
factors identiﬁ  ed in Figure 1 were signiﬁ  cant barriers to IST 
adherence (a study by Vasquez and colleagues [2003] further 
validated cost and forgetfulness as key barriers to medication 
adherence among RTRs). Based on these collective ﬁ  ndings, 
a clinical pharmacy services intervention was developed, with 
the overarching goal of improving the care of MCG RTRs.
In February 1997, a randomized controlled trial of our 
clinical pharmacy services intervention was implemented in 
the MCG renal transplant clinic which addressed the barriers 
to IST adherence described in Figure 1 (Chisholm et al 2001). 
Adults at least 18 years of age, who received their ﬁ  rst and 
only renal transplant at MCG between February 1997 and 
January 1999, were eligible to participate immediately fol-
lowing transplantation, and were enrolled into the study on 
a rolling basis (participants remained enrolled in the study 
for a 12-month period-the length of the intervention); the 
study was completed in January 2000. After consenting to 
participate in the study, RTRs were randomized into one 
of two groups, the intervention or the control. The RTRs 
in the intervention group (n = 12) received traditional 
care in combination with clinical pharmacy services. As 
part of the study protocol, on a monthly basis for the ﬁ  rst Patient Preference and Adherence 2008:2 289
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12 months post-transplant, a clinical pharmacist counseled 
RTRs assigned to the intervention group on their medication 
therapy, including providing instructions on how to properly 
take medications in order to promote medication adherence 
and health-related outcomes. Additional duties of the clinical 
pharmacist included: (1) reviewing RTRs’ medication 
histories with emphasis on optimizing medication therapy 
and minimizing adverse events; (2) encouraging adherence to 
medications; (3) increasing access to medication by enrolling 
RTRs in pharmaceutical manufacturers’ medication assis-
tance programs; and (4) providing recommendations to the 
nephrologists, other health care team members, and RTRs 
to achieve desired health outcomes. RTRs assigned to the 
control group (n = 12) also received traditional care from the 
interdisciplinary clinic team (standard of care), but were not 
provided clinical pharmacy services.
The sample had a mean age of 42.9 years (SD = 10.2) 
and was 75% male, 58% Caucasian, 38% African American, 
and 4% Hispanic (Chisholm et al 2001). The majority 
(66.7%) received their kidney from a deceased donor, and 
approximately 88% were prescribed cyclosporine. At the 
end of the study, RTRs assigned to the intervention group 
had a higher mean adherence rate compared to those in the 
control group (96.1% ± 4.7 vs 81.6% ± 11.5; p  0.001; 
Chisholm et al 2001). RTRs in the intervention group also 
remained adherent for a longer period of time during the 
12-month intervention compared to those RTRs assigned 
to the control group (a mean of 11 months vs. a mean of 
9 months to ﬁ  rst nonadherent month [ p  0.05]; nonadher-
ence was deﬁ  ned as an adherence rate of less than 80%; 
Chisholm et al 2001). It is important to note that although 
our study sample was too small to detect graft rejection 
and/or failure, other studies provide evidence of a signiﬁ  cant 
association between medication nonadherence and rejection/
failure (Vasquez et al 2003; Chisholm et al 2007). Based on 
this evidence, we speculate that the improvements in adher-
ence demonstrated by RTRs as a result of clinical pharmacy 
services may play a role in long-term graft maintenance 
and survival.
The clinical pharmacist’s efforts to eliminate 
cost as a barrier to adherence by enrolling RTRs in 
pharmaceutical manufacturers’ medication assistance 
programs was considered a particularly successful 
outcome of the clinical pharmacy services. As part of 
the evaluation of our clinical pharmacy services inter-
vention, we studied the cost-avoidance of enrolling 
qualiﬁ  ed patients into manufacturers’ immunosuppressant 
medication assistance programs (Chisholm et al 2000a). 
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Figure 1 Fishbone diagram of possible causes of nonadherence.
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The clinical pharmacist enrolled RTRs into assistance 
programs for immunosuppressant medications from 
January 1, 1998 through December 31, 1998 if they met 
the following criteria: (1) needed financial assistance 
to purchase their immunosuppressant medications, and 
(2) qualiﬁ  ed ﬁ  nancially for the manufacturers’ assistance 
programs. Sixty-one RTRs were enrolled in pharmaceutical 
manufacturers’ assistance programs and a net cost avoid-
ance of $69,233 for the year 1998 was calculated with a 
beneﬁ  t-to-cost ratio of approximately 4:1.
Supplemental randomized controlled trials examining this 
clinical pharmacy service program’s quality and impact of on 
RTRs’ health-related and economic outcomes have also been 
conducted. Compared to RTRs who did not receive clinical 
pharmacy services, RTRs who did receive clinical pharmacy 
services in the MCG renal transplant clinic (Table 1): 
(1) were more satisﬁ  ed with the quality of their health care 
(Chisholm et al 1999a); (2) experienced fewer adverse 
drug reactions (Chisholm et al 2000b); (3) experienced 
improvements in their blood pressure and blood glucose 
levels (Chisholm et al 1999b, 1999c, 2002); and (4) had 
lower mean total health care costs per RTR (Vollenweider 
et al 2001). Additionally, the clinical pharmacist provided 
physicians with 844 pharmacotherapeutic recommenda-
tions during the program’s initial (pilot) implementation 
period (Chisholm et al 2000c). Greater than 80% of the 
recommendations involved untreated indications, overdosage, 
subtherapeutic dosage, or medication use without an indica-
tion (Figure 2). Based upon the cumulative positive results 
of these studies, clinical pharmacy services are ongoing at 
the MCG renal transplant clinic.
In conclusion, clinical pharmacy services resulted in 
signiﬁ  cant improvements in RTRs’ clinical and economic 
outcomes. Although UNOS supports the use of a clinical 
pharmacist as a member of the transplant team and clinical 
pharmacy services have had positive effects in the manage-
ment of other chronic disease states, little evidence from 
randomized controlled trials and other studies of clinical 
pharmacy services to improve post-transplant care for RTRs 
was found in the literature. We recognize the challenges 
involved in implementing clinical pharmacy services among 
transplant recipients including lack of knowledge/experience 
in designing and administering such services as well as 
difficulty in procuring funding and reimbursement for 
services. Yet, the success of our program demonstrates that 
clinical pharmacy services are feasible within an outpatient 
transplant clinic and have a beneﬁ  cial impact on outcomes 
among transplant recipients. Thus, this article addresses a 
strategy for effective implementation of clinical pharmacy 
services and may provide a template for use in other 
Table 1 Impact of clinical pharmacy services at MCG renal transplant clinic on renal transplant recipients’ outcomes
Reference Study 
design
Number of RTRs Outcome(s) examined Results
Chisholm et al 1999b RCT 18 (intervention); 15 (control) Blood pressure levels Signiﬁ  cant SBP and DBP level 
improvement in intervention 
group (p  0.05)
Chisholm et al 1999c RCT 18 (intervention); 15 (control) Blood glucose levels Signiﬁ  cant fasting blood 
glucose level improvement in 
intervention group (p  0.05)
Chisholm et al 1999a RCT 21 (intervention); 17 (control) Satisfaction with health 
care quality
Intervention group more 
satisﬁ  ed with health care 
Quality (p  0.05)
Chisholm et al 2000b RCT 28 (intervention); 26 (control) Adverse drug reactions Signiﬁ  cantly fewer ADRs in 
intervention group (p  0.05)
Vollenweider et al 2001 RCT 26 (intervention); 28 (control) Health care costs Intervention group had mean 
total costs of $2614 less 
per RTR than control group; 
clinical pharmacy services 
results in cost savings of 
$192,757
Chisholm et al 2002 RCT 13 (intervention); 10 (control) Blood pressure 
of African-American RTRs
Signiﬁ  cant SBP and DBP level 
improvement in intervention 
group (p  0.05)
Abbreviations: ADR, adverse drug reaction; DBP, diastolic blood pressure; MCG, Medical College of Georgia; RCT, randomized controlled trial; RTR, renal transplant recipient; 
SBP, systolic blood pressure.Patient Preference and Adherence 2008:2 291
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outpatient transplant care settings. Future studies should 
focus on implementing clinical pharmacy services in other 
transplant clinics, evaluating modiﬁ  cations to the clinical 
pharmacy program that will promote cost-effectiveness 
while maintaining positive adherence and health outcomes 
(such as reducing the time period for provision of clinical 
pharmacy services), and assessing the long-term impact of 
clinical pharmacy services in the transplant population.
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